Skip to content
Algiers 24°C
Advertisement

Algeria

Pharmaceutical Sector Innovation: Saidal Launches Type 2 Diabetes Drug

Saidal Group has introduced 'Dapaflox', a new medication for type 2 diabetes, aimed at preventing cardiovascular and kidney complications. This launch underscores Algeria's commitment to expanding local pharmaceutical production and improving public health services.

Pharmaceutical Sector Innovation: Saidal Launches Type 2 Diabetes Drug

The Saidal Group has officially launched 'Dapaflox', a new medication designed to treat type 2 diabetes and prevent its associated cardiovascular and kidney complications. The introduction took place at a scientific conference held in Algiers under the theme "Convergence: a common approach." Key figures present included Younes Bouarara, Director General of Saidal Group, and Abdelhakim Boualdis, Secretary-General of the Ministry of Pharmaceutical Industry, who attended on behalf of Minister Wassim Gouidri. Also in attendance were Cherif Dellih, Director General of the National Agency for Pharmaceutical Products, and Professor Ammar Tabaibia, head of the multidisciplinary expert committee for the national list of essential medicines, alongside various medical specialists and Saidal executives.

This launch marks a new phase in the development of the Saidal Group, aligning with its strategic objectives to diversify therapeutic options and enhance its industrial and technological capabilities. The group emphasized its commitment to fostering pharmaceutical innovation while ensuring that high-quality medicines are accessible and affordable for patients across the country. This initiative highlights Saidal's ongoing efforts to strengthen its presence in the national pharmaceutical market and expand its portfolio of locally produced treatments.

From a broader national perspective, the introduction of 'Dapaflox' supports President Abdelmadjid Tebboune's strategic vision for reinforcing health sovereignty and improving the management of chronic diseases. The Secretary-General of the Ministry of Pharmaceutical Industry underscored the importance of a comprehensive approach to type 2 diabetes, encompassing early detection, consistent medical monitoring, and the prevention of complications. This governmental direction promotes local production and encourages innovation to reduce reliance on imported medications for public health needs.

The new medication is anticipated to significantly enrich the range of locally available therapeutic alternatives for individuals with type 2 diabetes, thereby contributing to the national health strategy. It also demonstrates the growing innovation capacity within the Algerian pharmaceutical sector, solidifying its role in meeting the nation's healthcare demands.

Comments

Moderated before publication
ANEP Régie Publicitaireالصفقات العمومية